Neurobiological studies of sensory gating in schizophrenia.
The sensory disturbance in schizophrenia is often described as an inability to filter out extraneous noise from meaningful sensory inputs. The neurobiological basis of this inability to filter has been examined using auditory evoked potentials, which are computerized averages of the brain's electrical response to sound. The sounds are presented in pairs to test the ability of the brain to inhibit, or gate, its response to a repeated stimulus. Schizophrenic patients lack the ability to gate the neuronal response shown by a particular wave, the P50 wave. The measurement of this deficit in human subjects and the exploration of its neurobiology in animals has produced evidence about several issues in the pathophysiology of schizophrenia: (1) the role of dopamine in improvement of sensory function in schizophrenic patients treated with neuroleptic drugs, (2) the interaction between familial or genetic deficits in sensory functioning in schizophrenic patients and possible abnormalities in dopamine metabolism, and (3) a mechanism by which noradrenergic hyperactivity in mania and other psychiatric illnesses might mimic some pathophysiological deficits in schizophrenia.
D014150:Antipsychotic Agents / Q000627:therapeutic use; D001143:Arousal / Q000502:physiology*; D001288:Attention / Q000502:physiology*; D001307:Auditory Perception / Q000502:physiology*; D001714:Bipolar Disorder / Q000503:physiopathology; D001921:Brain / Q000503:physiopathology; D004298:Dopamine / Q000378:metabolism; D004569:Electroencephalography; D005072:Evoked Potentials, Auditory / Q000187:drug effects; D006801:Humans; D012307:Risk Factors; D012559:Schizophrenia / Q000235:genetics / Q000503:physiopathology*; D012565:Schizophrenic Psychology; D009435:Synaptic Transmission / Q000187:drug effects
D014150:Antipsychotic Agents; D004298:Dopamine